Rigel Pharmaceuticals Inc. (RI2)
XMUN 
Summary
RI2 Chart
Rigel Pharmaceuticals: A Four-Drug Company With A Clinical Catalyst Ahead
Rigel Pharmaceuticals in-licensed Veppanu, a drug for the treatment of certain breast cancer patients, targeting a $1B market, with revenues expected as early as Q3'26. Q2'26 saw strong sales growth from Tavalisse and Rezlidhia, offsetting Gavreto's middling performance. RIGL guides $285M–$295M 2026 revenues, excluding Veppanu upside. Upcoming R289 phase 1b data for LR-MDS and future readouts from Veppanu and Rezlidhia trials provide additional growth catalysts.
Rigel Pharmaceuticals: The Easy Money Has Been Made (Rating Downgrade)
Rigel's Q2 beat big ($78.7M revenue, $0.88 EPS), driven by TAVALISSE, but GAVRETO's year-over-year decline is concerning. Guidance raise came from contract revenue, not accelerating core product sales; net product sales guidance unchanged. VEPPANU is strategically sound but adds only incremental value after upfront payments, milestones, and high royalties.
Rigel Pharmaceuticals, Inc. (RIGL) Q2 2026 Earnings Call Transcript
Rigel Pharmaceuticals, Inc. (RIGL) Q2 2026 Earnings Call Transcript
Rigel Pharmaceuticals Inc. (RI2) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Rigel Pharmaceuticals Inc. ever had a stock split?
Rigel Pharmaceuticals Inc. Profile
| Biotechnology Industry | Healthcare Sector | Raul R. Rodriguez CEO | XMUN Exchange | US7665597024 ISIN |
| US Country | 173 Employees | - Last Dividend | 27 Jun 2024 Last Split | 29 Nov 2000 IPO Date |
Overview
Rigel Pharmaceuticals, Inc. is a forward-thinking biotechnology company deeply engaged in the discovery, development, and provision of innovative therapies aimed at improving the lives of patients dealing with hematologic disorders and cancer. Originating in 1996 and based out of South San Francisco, California, Rigel Pharmaceuticals has cemented its position in the biotech industry by focusing on cutting-edge research and strategic collaborations with key institutions such as The University of Texas MD Anderson Cancer Center. The company's pursuit of novel therapeutic solutions encompasses a robust pipeline of clinical and preclinical programs designed to address unmet medical needs in autoimmunity, cancer, and hematologic conditions.
Products and Services
- Tavalisse
- Rezlidhia
- GAVRETO
- R289 (Oral IRAK1/4 Inhibitor)
- RIPK1 Inhibitor Program
An oral spleen tyrosine kinase inhibitor specifically formulated for adult patients suffering from chronic immune thrombocytopenia (ITP). This innovative treatment represents Rigel's commitment to enhancing the quality of life for patients contending with this challenging autoimmune condition.
A groundbreaking, non-intensive monotherapy designed for adult patients with relapsed or refractory acute myeloid leukemia (AML) exhibiting a susceptible isocitrate dehydrogenase-1 (IDH1) mutation, as confirmed by an FDA-approved test. Rezlidhia underscores Rigel's focus on addressing critical gaps in cancer care, offering hope to those battling this formidable disease.
A once-daily, orally administered small molecule kinase inhibitor targeted at adult patients with metastatic RET fusion-positive non-small cell lung cancer, as well as adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. GAVRETO exemplifies Rigel's precision in developing treatments that target specific genetic markers, paving the way for personalized medicine in oncology.
Currently in Phase 1b clinical trials, R289 is an oral IRAK1/4 Inhibitor being explored for its potential in treating a range of conditions, including hematology-oncology, autoimmune, and inflammatory diseases. This investigational compound reflects Rigel's dedication to exploring new frontiers in medicine to combat a broad spectrum of diseases.
Part of a collaborative effort with Eli Lilly and Company, this program focuses on the development of a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, highlighting Rigel's strategy of partnering with industry leaders to accelerate the development of innovative therapies.
Furthermore, Rigel's dynamic approach to drug development includes strategic alliances with BerGenBio ASA and Daiichi Sankyo, through which it advances additional product candidates into clinical development, reinforcing its commitment to bringing transformative treatments to market.
